<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7307812\results\search\disease\results.xml">
  <result pre="the use of amiodarone, simvastatin, pioglitazone and curcumin. In mild" exact="infections" post="(sore throat, cough) we advocate prompt local treatment for"/>
  <result pre="for the naso-pharynx (inhalations; aerosols; nebulizers); for moderate to severe" exact="infections" post="we propose a tried-and-true treatment: the combination of arginine"/>
  <result pre="is organized in three sections: i) Clinical aspects of COVID-19;" exact="acute" post="respiratory distress syndrome (ARDS); known treatments; ii) Structure and"/>
  <result pre="organized in three sections: i) Clinical aspects of COVID-19; acute" exact="respiratory" post="distress syndrome (ARDS); known treatments; ii) Structure and functions"/>
  <result pre="three sections: i) Clinical aspects of COVID-19; acute respiratory distress" exact="syndrome" post="(ARDS); known treatments; ii) Structure and functions of SARS-CoV2"/>
  <result pre="sepsis arginine ascorbate coronavirus 1. Clinical aspects of COVID-19 infections;" exact="acute" post="respiratory distress syndrome (ARDS); known and potential treatments In"/>
  <result pre="arginine ascorbate coronavirus 1. Clinical aspects of COVID-19 infections; acute" exact="respiratory" post="distress syndrome (ARDS); known and potential treatments In China,"/>
  <result pre="coronavirus 1. Clinical aspects of COVID-19 infections; acute respiratory distress" exact="syndrome" post="(ARDS); known and potential treatments In China, the first"/>
  <result pre="for cancer, 6.0% for hypertension, 7.3% for diabetes, 10.5% for" exact="cardiovascular disease;" post="for intensive care patients CFR was 49.0%. Similar data"/>
  <result pre="identified 3 biological markers associated with the severity of the" exact="infection" post="and progression to ARDS and death: i) neutrophilia; ii)"/>
  <result pre="ii) administering methylprednisolone to patients with ARDS was associated with" exact="lower" post="risk of death. In Europe there was a higher"/>
  <result pre="from Germany (9) showed that ~1/3 of admitted patients had" exact="leucopenia" post="and most of these (80%) had lymphopenia; C-reactive protein"/>
  <result pre="an ARDS patient population was identified which comprised ~30% of" exact="total" post="ARDS cases, had higher levels of IL-6 and IL-8,"/>
  <result pre="opposite characteristics. The former has low levels of IL-6, IL-8," exact="tumor" post="necrosis factor receptor 1 (TNFr1), lower mortality as well"/>
  <result pre="levels of IL-6, IL-8, tumor necrosis factor receptor 1 (TNFr1)," exact="lower" post="mortality as well as higher number of ventilator-free days,"/>
  <result pre="critically-ill COVID-19 patients, increased LDH levels are likely associated with" exact="acidosis" post="and if low blood pressure is also present, before"/>
  <result pre="pathways of inflammation, increased levels of eosinophil- and neutrophil-derived proteins," exact="epithelial" post="and endothelial injury, matrix metalloproteinase 7 (MMP7), Î±- and"/>
  <result pre="mechanistic determinism, and this is especially true in patients with" exact="chronic" post="diseases or co-morbid conditions, where modifications of physiological pathways"/>
  <result pre="inflammation are simultaneously affected in ARDS, including coagulation, endothelial and" exact="epithelial" post="injury pathways (apoptosis) and healing (fibrosis) in lungs. A"/>
  <result pre="healing (fibrosis) in lungs. A unique molecular signature of lethal" exact="infection" post="with another respiratory virus (PR8, an influenza virus) showed"/>
  <result pre="lungs. A unique molecular signature of lethal infection with another" exact="respiratory" post="virus (PR8, an influenza virus) showed over-activation of pro-inflammatory"/>
  <result pre="a positive feedback loop; a dose-dependent survival was seen with" exact="partial" post="neutrophil depletion in this type of lethal infection. Comparing"/>
  <result pre="partial neutrophil depletion in this type of lethal infection. Comparing" exact="viral" post="replication in non-lethal vs. lethal infection they had similar"/>
  <result pre="of lethal infection. Comparing viral replication in non-lethal vs. lethal" exact="infection" post="they had similar viral replication rates, but the lethal"/>
  <result pre="viral replication in non-lethal vs. lethal infection they had similar" exact="viral" post="replication rates, but the lethal infection had increased viral"/>
  <result pre="infection they had similar viral replication rates, but the lethal" exact="infection" post="had increased viral titers in the lungs, and also"/>
  <result pre="similar viral replication rates, but the lethal infection had increased" exact="viral" post="titers in the lungs, and also increased early pro-inflammatory"/>
  <result pre="in induction of IFN in airway epitlelial cells resulting in" exact="vascular" post="leakage and lung damage were made in SARS and"/>
  <result pre="highly and rapidly effective at inhibiting cytokine-mediated neutrophil chemotaxis and" exact="respiratory" post="burst in a variety of therapeutic contexts (27). Efficacy"/>
  <result pre="therapeutic contexts (27). Efficacy of Dapsone in the treatment of" exact="Pneumocystis pneumonia" post="suggests it will penetrate the lung tissue sufficiently to"/>
  <result pre="contexts (27). Efficacy of Dapsone in the treatment of Pneumocystis" exact="pneumonia" post="suggests it will penetrate the lung tissue sufficiently to"/>
  <result pre="difficulties, malaise, fever, chills, diarrhea, generalized myalgia, drowsiness, dyspnea, and" exact="pneumonia" post="are similar in SARS-CoV2, MERS-CoV, and SARS CoV infections"/>
  <result pre="and pneumonia are similar in SARS-CoV2, MERS-CoV, and SARS CoV" exact="infections" post="(29), but COVID-19 differentiates itself from MERS and SARS"/>
  <result pre="much to the fact that infectivity is not restricted to" exact="symptomatic" post="patients (30); however, we can improve therapeutic strategies with"/>
  <result pre="types of molecules: RNA and proteins; RNA encodes for 27" exact="viral" post="proteins, of which 16 are non-structural proteins (nsps), and"/>
  <result pre="(M), and small envelope protein (E). The N-protein binds to" exact="viral" post="RNA, encloses it in a capsid and assists RNA"/>
  <result pre="in a capsid and assists RNA synthesis and folding during" exact="viral" post="replication; it also modifies host responses, cell cycle and"/>
  <result pre="and gene translation, and after RNA replication it guides the" exact="viral" post="membrane proteins for viral assembly. The S-protein is essential"/>
  <result pre="after RNA replication it guides the viral membrane proteins for" exact="viral" post="assembly. The S-protein is essential for attachment and fusion"/>
  <result pre="open reading frames (ORFs); this peculiarity increasing the efficacy of" exact="viral" post="replication and mutagenesis, and making it more difficult to"/>
  <result pre="of different lengths; first ORF has ~10,000 nucleotides (~2/3 of" exact="viral" post="RNA) and encodes nsps 1-16, with the structural and"/>
  <result pre="to heme and ORF8 to porphyrins (37); heme inactivation increases" exact="viral" post="infectivity through inhibition of the host innate antiviral response"/>
  <result pre="enzymes such as nitric oxide synthase (detailed below); also increases" exact="viral" post="permeation of tissues via porphirin binding and tissue destruction"/>
  <result pre="are antigens for SARS-CoV (40). The binding energy between the" exact="viral" post="S protein and host ACE2 receptor is higher in"/>
  <result pre="versus SARS-CoV (-50.6 kcal/mol vs. -78.6 kcal/mol) suggesting a more" exact="stable" post="bond (41); at the same time the affinity of"/>
  <result pre="differential infectivity (42). The S protein is a class I" exact="viral" post="fusion protein like the influenza virus hemagglutinin (HA); SARS-CoV2"/>
  <result pre="trypsin, elastase, cathepsin L) (44,45), and the cell surface from" exact="respiratory" post="epithelial cells has abundant TMPRSS2 and trypsin-like protease (46)."/>
  <result pre="elastase, cathepsin L) (44,45), and the cell surface from respiratory" exact="epithelial" post="cells has abundant TMPRSS2 and trypsin-like protease (46). Interestingly,"/>
  <result pre="has abundant TMPRSS2 and trypsin-like protease (46). Interestingly, human airway" exact="epithelial" post="cells can be infected by SARS-CoV even when proteases"/>
  <result pre="or the endosomal protease will not prevent, but only depress" exact="viral" post="cell entry; however, a combination of two substances, camostat"/>
  <result pre="substances, camostat and EST, a cathespsin inhibitor effectively blocked the" exact="viral" post="entry into cells. SARS-CoV2-infected cells aggregate to form syncytiums;"/>
  <result pre="Ca2+ concentration in its cell environment, and calcium chelators inhibit" exact="viral" post="fusion and cell entry. Thus it was observed that"/>
  <result pre="perform essential functions in immune antagonism through formation of the" exact="viral" post="replication complex and double membrane vesicles which shield the"/>
  <result pre="viral replication complex and double membrane vesicles which shield the" exact="viral" post="RNA, viral RNA proofreading, binding of nucleic acid and"/>
  <result pre="complex and double membrane vesicles which shield the viral RNA," exact="viral" post="RNA proofreading, binding of nucleic acid and helicase activity"/>
  <result pre="the SARS-CoV2 proteins. Besides needing to ensure the entry of" exact="viral" post="material into cells and subsequent replication, the viral proteins"/>
  <result pre="entry of viral material into cells and subsequent replication, the" exact="viral" post="proteins and RNA also need to evade the host"/>
  <result pre="evade the host immune system, and because the success of" exact="viral infection" post="depends on the impairment of the host antiviral response,"/>
  <result pre="the host immune system, and because the success of viral" exact="infection" post="depends on the impairment of the host antiviral response,"/>
  <result pre="the host antiviral response, this aspect deserves special attention. Airway" exact="epithelial" post="cells are able to prevent viral infections through multiple"/>
  <result pre="deserves special attention. Airway epithelial cells are able to prevent" exact="viral" post="infections through multiple mechanisms. The airway surface liquid (ASL)"/>
  <result pre="special attention. Airway epithelial cells are able to prevent viral" exact="infections" post="through multiple mechanisms. The airway surface liquid (ASL) is"/>
  <result pre="chemokines, host restriction factors) which block different steps in the" exact="viral" post="replication and are activated by specific cell sensors/receptors. Interferons"/>
  <result pre="which alter host cell cycle, translation and apoptosis, virus entry," exact="viral" post="RNA availability, stability and translation, particle and budding (50)."/>
  <result pre="the respective cell receptors - RIG-I-like receptors (RLR); and the" exact="melanoma" post="differentiation-associated protein 5 (MDA5), both of which have the"/>
  <result pre="antiviral signaling protein (MAVS). Besides RIG-1 and MDA5, other cellular" exact="viral" post="RNA sensors are known: the protein kinase RNA-activated (PKR),"/>
  <result pre="host cell translation and helps activate the NF-ÎºB. Early in" exact="infection" post="the antiviral response is driven by the peroxisomal MAVS,"/>
  <result pre="I IFNs are produced in and activate most cells, while" exact="type III" post="IFN (IFN-Î») mostly mucosal cells; they activate very similar"/>
  <result pre="cells are thought to have RLR and PKR receptors for" exact="viral" post="nucleic acids, while toll-like receptors (TLRs) are present in"/>
  <result pre="blocking IFN-Î² production by de-ubiquitination (DUB) of RIG-1 and other" exact="viral" post="sensors and effectors (56). Microarrays helped identify the proteins"/>
  <result pre="and effectors (56). Microarrays helped identify the proteins through which" exact="viral" post="particles can antagonize host immune responses: 13 proteins were"/>
  <result pre="glycosilation of the ACE2 receptor. Besides inhibiting the S protein-induced" exact="viral" post="fusion (59), and the PlPro protease (60) chloroquine can"/>
  <result pre="attack on hemoglobin (37) with porphirin formation. Protease inhibitors target" exact="viral" post="nsps needed for its replication, such as the RNA-dependent"/>
  <result pre="RNA-dependent RNA polymerase (RdRp) inhibited by ribavirin (which also inhibits" exact="viral" post="mRNA capping); the 3C-like protease (3CLpro) is inhibited by"/>
  <result pre="better results compared to ribavirin, which was associated with anemia," exact="hypoxia" post="and increased risk of death in SARS patients (61)."/>
  <result pre="were shown, however, to be ineffective especially in severe CoV" exact="infections" post="(48); recent data on SARS-CoV2 suggest that more specific"/>
  <result pre="bind the SARS-CoV-2 spike protein and are known to reduce" exact="lung inflammation," post="include GSK1838705A, BMS195614, GSK1838705A, which inhibit the insulin like"/>
  <result pre="eptifibatide acetate, an inhibitor of platelet aggregation already tested in" exact="septic shock;" post="and the Abelson (Abl) kinase inhibitor GNF5, known to"/>
  <result pre="Abelson (Abl) kinase inhibitor GNF5, known to inhibit replication of" exact="Dengue" post="virus, which deserves further attention. It was shown that"/>
  <result pre="the Abl2 kinase inhibitors GNF5/GNF2/imatinib inhibit the fusion of the" exact="viral" post="and endosomal membrane, an early stage of viral infection."/>
  <result pre="of the viral and endosomal membrane, an early stage of" exact="viral infection." post="GNF5/GNF2/imatinib also inhibit the formation of cell syncitia before"/>
  <result pre="syncitia before the hemifusion step, effectively blocking membrane fusion and" exact="viral" post="entry (67). Finally, 3 drugs deserve special attention for"/>
  <result pre="decrease macrophage activation. The third drug is probably the best" exact="viral" post="fusion inhibitor, RS 504393, which can bind both the"/>
  <result pre="thickening; moreover, it is also a selective antagonist of the" exact="monocyte" post="chemoattractant protein-1 (MCP-1) receptor CCR2, blocks the upregulation of"/>
  <result pre="either chloroquine or hydroxychloroquine based on their binding energy with" exact="viral" post="proteases (68), more information is given in Table III."/>
  <result pre="viral proteases (68), more information is given in Table III." exact="Local" post="treatment and IFNs. Based on the observation that the"/>
  <result pre="infections, with subsequent over-activation of neutrophils in the lung and" exact="vascular" post="leakage (54), IFN-stimulating substances administered by inhalation showed efficacy"/>
  <result pre="vitro and in vivo. Inhaled substances have the advantage of" exact="lower" post="volume of distribution (ASL has a volume of 20-30"/>
  <result pre="volume of 20-30 ml) and can act early in COV" exact="infection" post="during the viral fusion process, inhibiting the binding of"/>
  <result pre="ml) and can act early in COV infection during the" exact="viral" post="fusion process, inhibiting the binding of its S protein"/>
  <result pre="induce differentiation of mDC, promote Th1 activation with IL-12 and" exact="type I" post="IFN production, the activation of the innate immune response"/>
  <result pre="basic aminoacids arginine and lysine also showed excellent inhibition of" exact="viral" post="fusion (75). Another intranasal-administered peptide, EK1, which contains the"/>
  <result pre="from the binding motif of the S protein has inhibited" exact="infection" post="by many human coronaviruses (46); its administration in mice"/>
  <result pre="many human coronaviruses (46); its administration in mice reduced lung" exact="viral" post="titers by 1,000-fold 2014 (76) and its lipidation, EK1C4,"/>
  <result pre="to patients via inhalations, however, affinity amino acids have showed" exact="limited" post="benefits depending on the timing of administration and prompts"/>
  <result pre="further analysis of IFN actions. Similarly to the neutrophilia and" exact="lymphopenia" post="observed in severe COVID-19 patients, fatal SARS infection is"/>
  <result pre="neutrophilia and lymphopenia observed in severe COVID-19 patients, fatal SARS" exact="infection" post="is associated with high IFN and ISGs expression and"/>
  <result pre="ISGs expression and low T cell and antibody activity, while" exact="viral" post="clearance needs increased T cell responses (25). The immune"/>
  <result pre="infection, the immunopathological events are mostly IFN-I-dependent and independent of" exact="viral" post="replication; IFN-Î±/Î² receptor (IFNAR) receptor ablation or neutrophil depletion"/>
  <result pre="IFN-Î±/Î² receptor (IFNAR) receptor ablation or neutrophil depletion avoided lethal" exact="infection" post="but did not affect the viral load. TNF inhibition"/>
  <result pre="neutrophil depletion avoided lethal infection but did not affect the" exact="viral" post="load. TNF inhibition improved lymphopenia, which is not unexpected"/>
  <result pre="and plasminogen activator inhibitor 1 (Serpin1) is prevented in the" exact="absence of" post="either one, resulting in excessive pro-inflammatory modulation. During early"/>
  <result pre="in preventing early induction of innate responses, by removing the" exact="viral" post="dsRNA that would otherwise trigger host cell dsRNA responses,"/>
  <result pre="responses, including IFN, PKR and OAS/RNase L, and delaying the" exact="viral" post="RNA cytoplasmic sensing mediated by MDA5. During early stages"/>
  <result pre="early stages of SARS infection, IFN-Î³ presence is associated with" exact="viral" post="clearance and infection resolution; IFN-Î³ is synthesized mainly by"/>
  <result pre="SARS infection, IFN-Î³ presence is associated with viral clearance and" exact="infection" post="resolution; IFN-Î³ is synthesized mainly by activated T cells"/>
  <result pre="IFN-Î±/Î² (type I) have synergistic actions; given alone neither inhibits" exact="viral" post="replication, but administration of both inhibited viral replication by"/>
  <result pre="alone neither inhibits viral replication, but administration of both inhibited" exact="viral" post="replication by 3000-fold at 24 h, with stronger inhibition"/>
  <result pre="IFNs; all IFNs induced complement component C1r, IFN-induced nuclear phosphoprotein," exact="vascular" post="endothelial growth factor (VEGF)-related protein (VRP or VEGF-C), and"/>
  <result pre="each IFN preferentially induced specific molecules: IFN-Î±, somatic cytochrome c;" exact="hepatitis" post="C-associated p44; pyridoxal kinase; and lysosomal acid lipase (LIPA);"/>
  <result pre="hypoxia-inducible factor-1 (HIF-1Î±) which regulates apoptosis and cell response to" exact="hypoxia" post="via expression of VEGF, p53, p21; IFN-Î³, mitochondrial 3-ketoacyl-CoA"/>
  <result pre="IFN-Î³, mitochondrial 3-ketoacyl-CoA thiolase; poly (ADP-ribose) polymerase; proton-ATPase-like protein. Both" exact="type I" post="and type II IFNs increase expression of the CH25H"/>
  <result pre="thiolase; poly (ADP-ribose) polymerase; proton-ATPase-like protein. Both type I and" exact="type II" post="IFNs increase expression of the CH25H gene which codes"/>
  <result pre="in their lungs, activated via the STAT6 pathway, and developed" exact="pulmonary" post="fibrosis (83). The modifications induced by the SARS-Cov infection"/>
  <result pre="developed pulmonary fibrosis (83). The modifications induced by the SARS-Cov" exact="infection" post="in host cells were also investigated via a library"/>
  <result pre="complex lipids (inositol phosphate, nicotinate, nicotinamide), intermediates needed in SARS-CoV" exact="infection" post="and probably linked to prenylation. The strongest proviral activation"/>
  <result pre="potentiating of RIG-I ubiquitination; hemoglobin is present in lung, kidney," exact="peripheral" post="blood mononuclear and other cell lines (38,85), and SARS-CoV2"/>
  <result pre="through degradation of tryptophan and kynurenines; its role in SARS-CoV2" exact="infection" post="was not explored but likely is important (86). Activation"/>
  <result pre="an IDO inhibitor; the role of IDO in the SARS-CoV2" exact="infection" post="and its immune evasion has not yet been explored."/>
  <result pre="been explored. The data above confirm that in severe CoV" exact="infection" post="the host immune system is mounting an imbalanced response"/>
  <result pre="the host immune system is mounting an imbalanced response to" exact="infection" post="which powerfully favors neutrophils/macrophages and inhibits the adaptive cellular"/>
  <result pre="by the virus, hemoglobin degradation and/or simultaneous actions of other" exact="viral" post="molecules (EndoU). However, it is possible that the delayed"/>
  <result pre="to the lack of activation in the early stage of" exact="infection" post="of the peroxisomal MAVS necessary for early IFN production"/>
  <result pre="of HSV-1 which blocks the peroxisomal MAVS (91), also the" exact="hepatitis C" post="virus protein NS3-4A, the capsid of the Dengue and"/>
  <result pre="the hepatitis C virus protein NS3-4A, the capsid of the" exact="Dengue" post="and West Nile virus, and the vMIA protein of"/>
  <result pre="cells lacking either peroxisomal or mitochondrial MAVS had an unusual" exact="biphasic" post="behavior, restricting viral replication in the first 24 h,"/>
  <result pre="peroxisomal or mitochondrial MAVS had an unusual biphasic behavior, restricting" exact="viral" post="replication in the first 24 h, but not at"/>
  <result pre="72 h, and showing that both organelles are necessary for" exact="viral" post="clearance (53). The functional status of peroxisomes can be"/>
  <result pre="impaired by poor oxidative status, low cellular pH (acidosis) and/or" exact="hypoxia" post="which is also seen in patients with chronic pathologies"/>
  <result pre="(acidosis) and/or hypoxia which is also seen in patients with" exact="chronic" post="pathologies or genetic deficiencies. pH-dependent viral actions. At the"/>
  <result pre="seen in patients with chronic pathologies or genetic deficiencies. pH-dependent" exact="viral" post="actions. At the surface of the respiratory epithelium low"/>
  <result pre="genetic deficiencies. pH-dependent viral actions. At the surface of the" exact="respiratory" post="epithelium low pH favors viral entry and replication by"/>
  <result pre="At the surface of the respiratory epithelium low pH favors" exact="viral" post="entry and replication by impairing the actions of the"/>
  <result pre="ASL being actively regulated by bicarbonate transport (49); another pH-lowering" exact="viral" post="activity is the formation of cell syncytiums. Lower intracellular"/>
  <result pre="intracellular pH favors the activity of the proteases needed for" exact="viral" post="replication, decreases the mitochondrial membrane potential and inactivates MAVS,"/>
  <result pre="impair the glycosylation of ACE2, an additional mechanism for blocking" exact="viral" post="fusion. The pH-dependent fusion of various viruses endocytosed into"/>
  <result pre="also decrease of lymphocyte function, lymphokine secretion and activation, while" exact="hypoxia" post="is potentiating these actions (97-101); acidosis is associated with"/>
  <result pre="secretion and activation, while hypoxia is potentiating these actions (97-101);" exact="acidosis" post="is associated with increased need for intensive care and"/>
  <result pre="addition, a low extra- and intra-cellular pH not only favors" exact="viral infection," post="but also impedes the antiviral action of known medication."/>
  <result pre="haemagglutinin (HA), induce a 0.2 unit pH modification and blocks" exact="viral" post="fusion; consequently some influenza strains developed a HA which"/>
  <result pre="of medication effectiveness (104). More aspects of pH modifications in" exact="viral" post="infections are discussed below; re-establishing physiological pH levels (7.35-7.45)"/>
  <result pre="medication effectiveness (104). More aspects of pH modifications in viral" exact="infections" post="are discussed below; re-establishing physiological pH levels (7.35-7.45) is"/>
  <result pre="significantly impact the immune functions and the host answer to" exact="viral infection," post="as it was found that individual variations exist in"/>
  <result pre="red cells, neuromuscular and central nervous systems, was associated with" exact="susceptibility to" post="ARDS; rs3848719 of ZNF335, zinc finger protein regulating lymphoblast"/>
  <result pre="nicotinamide phosphoribosyltransferase (NAMPT) with the -1535T allele associated with decreased" exact="susceptibility to" post="ARDS, and the -1001G variant with higher susceptibility to"/>
  <result pre="decreased susceptibility to ARDS, and the -1001G variant with higher" exact="susceptibility to" post="ARDS and mortality in a Caucasian population; other pathways"/>
  <result pre="lymphocyte signalling, calcium-induced apoptosis of T lymphocytes, B-cell development, and" exact="autoimmune" post="thyroid disease (106). Other genes associated with the pulmonary"/>
  <result pre="signalling, calcium-induced apoptosis of T lymphocytes, B-cell development, and autoimmune" exact="thyroid disease" post="(106). Other genes associated with the pulmonary injury type"/>
  <result pre="calcium-induced apoptosis of T lymphocytes, B-cell development, and autoimmune thyroid" exact="disease" post="(106). Other genes associated with the pulmonary injury type"/>
  <result pre="and autoimmune thyroid disease (106). Other genes associated with the" exact="pulmonary" post="injury type of ARDS are POPDC3 (expressed in cardiac"/>
  <result pre="are POPDC3 (expressed in cardiac and skeletal muscle, role in" exact="glioma" post="and muscular dystrophy), PDE4B (phosphodiesterase), ABCC1 (organic anion transporter"/>
  <result pre="(107). Using bioinformatic analysis for genetic associations with ARDS, a" exact="total" post="of 201 genes were found predominantly involved in pathways"/>
  <result pre="especially linked to innate immunity, reactive oxygen species, and endothelial" exact="vascular" post="signaling (108); it is worth noting that all these"/>
  <result pre="found an increase frequency of D allele in patients with" exact="hypoxia" post="(n=22) versus no hypoxia (n=22) (110). However, a larger"/>
  <result pre="of D allele in patients with hypoxia (n=22) versus no" exact="hypoxia" post="(n=22) (110). However, a larger study (n=168) evaluated the"/>
  <result pre="(n=168) evaluated the influence of ACE I/D polymorphism on SARS-CoV" exact="infection" post="susceptibility and development of ARDS in a Chinese population"/>
  <result pre="between the frequency of the D allele and presence of" exact="infection" post="or severe disease; the only factors associated with requirement"/>
  <result pre="lung injury and ACE-deficient mice had much better outcome in" exact="acute" post="lung injury (113). Also in animal models with acute"/>
  <result pre="in acute lung injury (113). Also in animal models with" exact="acute" post="inflammation it was shown that the renin angiotensin system"/>
  <result pre="bradykinin receptor also inhibited neutrophil chemotaxis induced by IL-8 and" exact="pulmonary" post="recruitment of neutrophils (114). Angiotensin II activates NF-ÎºB in"/>
  <result pre="and neutrophil chemotaxis (115). Moreover, angiotensin converting enzyme (ACE) affects" exact="pulmonary" post="vascular tone and permeability, epithelial cell apoptosis, and lung"/>
  <result pre="neutrophil chemotaxis (115). Moreover, angiotensin converting enzyme (ACE) affects pulmonary" exact="vascular" post="tone and permeability, epithelial cell apoptosis, and lung fibrosis"/>
  <result pre="angiotensin converting enzyme (ACE) affects pulmonary vascular tone and permeability," exact="epithelial" post="cell apoptosis, and lung fibrosis via fibroblast activation so"/>
  <result pre="affects pulmonary vascular tone and permeability, epithelial cell apoptosis, and" exact="lung fibrosis" post="via fibroblast activation so that RAS inhibitors may be"/>
  <result pre="from sepsis-induced ALI, by downregulating RAS which is involved in" exact="pulmonary" post="hypertension and pulmonary fibrosis; ACE2 expression increases after IFN-I"/>
  <result pre="sepsis-induced ALI, by downregulating RAS which is involved in pulmonary" exact="hypertension" post="and pulmonary fibrosis; ACE2 expression increases after IFN-I administration."/>
  <result pre="by downregulating RAS which is involved in pulmonary hypertension and" exact="pulmonary" post="fibrosis; ACE2 expression increases after IFN-I administration. SARS-CoV infection"/>
  <result pre="and pulmonary fibrosis; ACE2 expression increases after IFN-I administration. SARS-CoV" exact="infection" post="produces a rapid downregulation of ACE2 expression at cell"/>
  <result pre="levels of aminopeptidase P, which catabolizes bradykinin and was significantly" exact="lower" post="in hypertensive patients with a history of angio-oedema during"/>
  <result pre="the severity of the COVID-19 is less related to the" exact="viral" post="replication itself than to the host responses to the"/>
  <result pre="a pro-inflammatory, pro-apoptotic milieu, combined with lymphopenia, acidosis, coagulation and" exact="vascular" post="endothelium modifications and defective tissue repair with fibrosis in"/>
  <result pre="fibrosis in the lungs. Most treatments are focused on blocking" exact="viral" post="replication, however, in fatal cases irreversible changes and deterioration"/>
  <result pre="in fatal cases irreversible changes and deterioration occur even though" exact="viral" post="replication is essentially blocked. Therapeutic interventions which combine agents"/>
  <result pre="pathways modulating inflammation, innate immunity, reactive oxygen species, and endothelial" exact="vascular" post="signaling (108); all these pathways are modulated by NO"/>
  <result pre="function and number, especially important in patients with neutrophilia and" exact="lymphopenia" post="and finally it provides essential components and stimulates the"/>
  <result pre="of NOS in mice resulted in conversion of a resolving" exact="infection" post="by the ectromelia virus into fulminant mousepox (126). NO"/>
  <result pre="shown to be essential for native immune responses in many" exact="infections" post="and arginine availability is a critical factor for host"/>
  <result pre="arginine availability is a critical factor for host resistance to" exact="infection" post="(122). NO can pass through membranes, unlike complement and"/>
  <result pre="of infected cell by the immune system, which can be" exact="limited" post="by pathogens or tissue-specific differences (127). Reducing arginine availability"/>
  <result pre="than in plasma; it enhances chemotaxis, ROS generation, phagocytosis and" exact="viral" post="clearance, important for minimising necrosis and tissue damage (131)."/>
  <result pre="effects of NO (134) in virus-infected cells, and thus inhibiting" exact="viral" post="replication. It is also important to note that all"/>
  <result pre="anti-NOS and other IDO activities. In the case of SARS-CoV2" exact="infection" post="which directly antagonizes NO production, arginine provides both the"/>
  <result pre="Noting the essential role of arginine for immunity, an arginine" exact="deficiency" post="syndrome (ADS) was proposed, defined by pathological increase in"/>
  <result pre="the essential role of arginine for immunity, an arginine deficiency" exact="syndrome" post="(ADS) was proposed, defined by pathological increase in arginase,"/>
  <result pre="Î¶-chain, and presence of one or more of: trauma, cancer," exact="chronic" post="infection, liver necrosis, pulmonary hypertension; treatment for ADS include"/>
  <result pre="one or more of: trauma, cancer, chronic infection, liver necrosis," exact="pulmonary" post="hypertension; treatment for ADS include L-arginine and the arginase"/>
  <result pre="graphic representation of these actions are given in Fig. 4." exact="Multiple" post="authors noted that administration of ascorbate in chronic granulomatous"/>
  <result pre="Fig. 4. Multiple authors noted that administration of ascorbate in" exact="chronic" post="granulomatous disease led to consistent improvements (143,144); more recent"/>
  <result pre="Multiple authors noted that administration of ascorbate in chronic granulomatous" exact="disease" post="led to consistent improvements (143,144); more recent research showed"/>
  <result pre="the arginine-ascorbate antimicrobial synergy. Synergistic action of arginine-ascorbate for inhibiting" exact="viral" post="replication and achieving viral clearance is shown by the"/>
  <result pre="Synergistic action of arginine-ascorbate for inhibiting viral replication and achieving" exact="viral" post="clearance is shown by the combined effect of IFN-Î±"/>
  <result pre="and sufficient to completely block the replication and spread of" exact="myxoma" post="virus in human fibroblasts and to block the spread"/>
  <result pre="virus in human fibroblasts and to block the spread of" exact="vaccinia" post="virus and tanapox virus to neighboring cells. Nitric oxide"/>
  <result pre="function via IFN-Î³ (type II); their synergy ensures both decreased" exact="viral" post="replication and clearance. c) Stimulation of tissue repair. It"/>
  <result pre="molecules and pathways are involved in the immune response in" exact="viral infection" post="and individual variability can also have an important role."/>
  <result pre="and pathways are involved in the immune response in viral" exact="infection" post="and individual variability can also have an important role."/>
  <result pre="by inhibiting HIF-1Î± (152), which is stimulated by IFN-I (80);" exact="hypoxia" post="by inhibiting arginine intracellular synthesis is a deleterious factor"/>
  <result pre="synthesized in the liver and kidney (15-20 g daily) from" exact="citrulline" post="in the urea cycle, ~10% is used for creatine"/>
  <result pre="studies appear to be well tolerated by healthy individuals and" exact="cancer" post="patients without major side effects; significant elevation in IGF1"/>
  <result pre="for maintaining plasma levels &amp;gt;30 Âµg/ml, however, during stress and" exact="infections" post="the need for ascorbate intake exceeds 1,000 mg/day and"/>
  <result pre="We have found this treatment effective in many types of" exact="viral" post="infections, including common cold and flu (many of which"/>
  <result pre="cold and flu (many of which are caused by coronaviruses)," exact="herpes" post="labialis, zona zoster, and hepatitis C, including a chronic"/>
  <result pre="which are caused by coronaviruses), herpes labialis, zona zoster, and" exact="hepatitis C," post="including a chronic hepatitis C patient who had significant"/>
  <result pre="coronaviruses), herpes labialis, zona zoster, and hepatitis C, including a" exact="chronic hepatitis C" post="patient who had significant viral loads after 2 treatments"/>
  <result pre="herpes labialis, zona zoster, and hepatitis C, including a chronic" exact="hepatitis C" post="patient who had significant viral loads after 2 treatments"/>
  <result pre="C, including a chronic hepatitis C patient who had significant" exact="viral" post="loads after 2 treatments with ribavirin+interferon, and undetectable at"/>
  <result pre="years after intravenous arginine-ascorbate. Arginine-ascorbate in severely ill patients. Metabolic" exact="acidosis" post="is associated with hyper-inflammation in ARDS patients, and administration"/>
  <result pre="and administration of sodium bicarbonate for balancing pH can be" exact="limited" post="by electrolyte imbalance and/or cardiovascular pathology. Arginine administration can"/>
  <result pre="for balancing pH can be limited by electrolyte imbalance and/or" exact="cardiovascular" post="pathology. Arginine administration can improve pH via the buffering"/>
  <result pre="of NO (nitric oxide), which may induce relaxation of the" exact="vascular" post="smooth muscle has raised concerns (156,157). A very thorough"/>
  <result pre="(nitric oxide), which may induce relaxation of the vascular smooth" exact="muscle" post="has raised concerns (156,157). A very thorough review of"/>
  <result pre="sepsis (159) improved outcomes and decreased mortality; it also reversed" exact="septic shock" post="without hemodynamic instability (160). A better assessment of septic"/>
  <result pre="septic shock without hemodynamic instability (160). A better assessment of" exact="septic shock" post="patients can be done by using the ratio of"/>
  <result pre="and beneficial in critically ill patients, contributing to resolution of" exact="infection" post="and improving morbidity and mortality (158). Adding ascorbate makes"/>
  <result pre="mortality, decreased need for vasopressor and mechanical ventilation, but not" exact="lower" post="or higher doses (166). In a prospective randomised placebo-controlled"/>
  <result pre="or higher doses (166). In a prospective randomised placebo-controlled double" exact="blind" post="trial - CITRIS-ALI - ascorbate 50 mg/kg or placebo"/>
  <result pre="organ dysfunction scores (SOFA), inflammation marker CRP or thrombomodulin (for" exact="vascular" post="integrity) (167). However, patients treated with vitamin C had"/>
  <result pre="hypotensive patients, ascorbate should be administered first, followed by a" exact="lower" post="dose of arginine (ex 1500 mg ascorbate in 100-200"/>
  <result pre="administration of anticoagulant, heparin or fractionated heparin; for signs of" exact="porphyria" post="(spontaneous ecchymosis which do not change color) - chloroquine,"/>
  <result pre="for all patients and especially with high cholesterol, simvastatin for" exact="asthma" post="patients, Montelukast and/or fexofenadine or other lipophilic antihistaminic and"/>
  <result pre="of benefit in COVID-19 (4), and even with associated immune" exact="depression" post="favoring viral replication, it can be considered for short-term"/>
  <result pre="in COVID-19 (4), and even with associated immune depression favoring" exact="viral" post="replication, it can be considered for short-term in severely"/>
  <result pre="difficult to predict accurately the individual risk for developing severe" exact="disease" post="besides advanced age and existing co-morbid conditions. Unopposed or"/>
  <result pre="besides advanced age and existing co-morbid conditions. Unopposed or excessive" exact="viral" post="replication is an important pathogenic mechanism through which the"/>
  <result pre="of the body; besides a weakened immune response associated with" exact="chronic" post="pathologies (cardiovascular, renal, hepatic, autoimmune and neoplasic), the virus"/>
  <result pre="weakened immune response associated with chronic pathologies (cardiovascular, renal, hepatic," exact="autoimmune" post="and neoplasic), the virus has an advantage in tired"/>
  <result pre="also testing and treating early, as soon as possible after" exact="respiratory" post="symptoms. After infection and respiratory symptoms, prompt local treatment"/>
  <result pre="treating early, as soon as possible after respiratory symptoms. After" exact="infection" post="and respiratory symptoms, prompt local treatment is very important:"/>
  <result pre="as soon as possible after respiratory symptoms. After infection and" exact="respiratory" post="symptoms, prompt local treatment is very important: aerosol inhalation,"/>
  <result pre="sprays with propolis, argentum, basil, thyme, cumin will also help" exact="viral" post="inactivation and decrease inflammation. We propose arginine-ascorbate as the"/>
  <result pre="SARS-CoV2 and other coronaviruses, administered from the initial signs of" exact="infection" post="until its resolution. As much as NSAIDs (non-steroidal antiinflammatory"/>
  <result pre="be elevated in elderly patients, and further elevated by SARS-CoV" exact="infection" post="and in more severe forms of COVID-19 (73); however"/>
  <result pre="inhibitor) is useful for alleviating inflammation and pain, and if" exact="rhinitis" post="and conjunctive inflammation are present, an antihistaminic can be"/>
  <result pre="sore throat to allodynia, in patients with allergies, increased PGD2," exact="rheumatoid arthritis," post="and also for porphyria. Patients who cannot tolerate curcumin"/>
  <result pre="or amiodarone in patients with prolonged QT interval, COPD or" exact="lung fibrosis." post="Risk evaluation of CoV infected patients. Assessing the risk"/>
  <result pre="risk for progression to severe forms early on during CoV" exact="infection" post="is important for prompt individual treatment and medical resource"/>
  <result pre="imposing restriction on the whole population, knowing that 90% of" exact="infections" post="are asymptomatic or can be treated outside hospital; this"/>
  <result pre="panel for genetic risk factors which predispose to fatal CoV" exact="infections" post="(rs78142040, rs9605146, rs3848719; NAMPT - 1001G allele, POPDC3, PDE4B,"/>
  <result pre="professionals). However, in patients most at-risk - elderly and with" exact="chronic" post="co-morbidities, evaluation with different testing panels can reasonably assess"/>
  <result pre="serum protein electrophoresis - for asymptomatic patients, and adding for" exact="symptomatic" post="patients the CD3+, CD4+, CD8+ and NK counts (predictors"/>
  <result pre="CXCl-2 (106). Another approach to risk evaluation of severe COV" exact="infection" post="is measuring the high-sensitivity cardiac troponin (hs-cTnT), shown with"/>
  <result pre="to be a marker for end-organ damage in patients with" exact="chronic" post="pathologies (170); elevated troponin levels were also seen in"/>
  <result pre="through risk evaluation and prompt, effective treatments the burden of" exact="disease" post="can be greatly diminished for both individuals and whole"/>
  <result pre="References References 1WuZMcGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: Summary of a report"/>
  <result pre="report of 72 314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA32312391242202010.1001/jama.2020.2648 2YangXYuYXuJShuHXiaJLiuHWuYZhangLYuZFangMet al.Clinical course and outcomes of"/>
  <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: A single-centered, retrospective, observational studyLancet Respir"/>
  <result pre="retrospective, observational studyLancet Respir Med8475481202010.1016/S2213-2600(20)30079-532105632 3LiJYYouZWangQZhouZJQiuYLuoRGeXYThe epidemic of 2019-novel-coronavirus (2019-nCoV)" exact="pneumonia" post="and insights for emerging infectious diseases in the futureMicrobes"/>
  <result pre="3LiJYYouZWangQZhouZJQiuYLuoRGeXYThe epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging" exact="infectious diseases" post="in the futureMicrobes Infect228085202010.1016/j.micinf.2020.02.00232087334 4WuCChenXCaiYXiaJZhouXXuSHuangHLiZhangL ZhouXDuCet al.Risk factors associated"/>
  <result pre="in the futureMicrobes Infect228085202010.1016/j.micinf.2020.02.00232087334 4WuCChenXCaiYXiaJZhouXXuSHuangHLiZhangL ZhouXDuCet al.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
  <result pre="the futureMicrobes Infect228085202010.1016/j.micinf.2020.02.00232087334 4WuCChenXCaiYXiaJZhouXXuSHuangHLiZhangL ZhouXDuCet al.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
  <result pre="Infect228085202010.1016/j.micinf.2020.02.00232087334 4WuCChenXCaiYXiaJZhouXXuSHuangHLiZhangL ZhouXDuCet al.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
  <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, ChinaJAMA Intern Med31320202020 (Epub ahead"/>
  <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, ChinaJAMA Intern Med31320202020 (Epub ahead of print)10.1001/jamainternmed.2020.0994"/>
  <result pre="Med38220122022202010.1056/NEJMoa200450032227758 11FarsalinosKNiauraRLe HouezecJBarbouniATsatsakisAKouretasDVantarakisAPoulasKEditorial: Nicotine and SARS-CoV-2: COVID-19 may be a" exact="disease" post="of the nicotinic cholinergic systemToxicol Rep7658663202010.1016/j.toxrep.2020.04.012 12CalfeeCSDelucchiKParsonsPEThompsonBTWareLBSubphenotypes in acute"/>
  <result pre="a disease of the nicotinic cholinergic systemToxicol Rep7658663202010.1016/j.toxrep.2020.04.012 12CalfeeCSDelucchiKParsonsPEThompsonBTWareLBSubphenotypes in" exact="acute" post="respiratory distress syndrome: Latent class analysis of data from"/>
  <result pre="disease of the nicotinic cholinergic systemToxicol Rep7658663202010.1016/j.toxrep.2020.04.012 12CalfeeCSDelucchiKParsonsPEThompsonBTWareLBSubphenotypes in acute" exact="respiratory" post="distress syndrome: Latent class analysis of data from two"/>
  <result pre="Respir Med2611620201410.1016/S2213-2600(14)70097-924853585 13WilsonJGCalfeeCSARDS subphenotypes: Understanding a heterogeneous syndromeCrit Care24102202010.1186/s13054-020-2778-x32204722 14FamousKRDelucchiKWareLBKangelarisKNLiuKDThompsonBTAcute" exact="respiratory" post="distress syndrome subphenotypes respond differently to randomized fluid management"/>
  <result pre="13WilsonJGCalfeeCSARDS subphenotypes: Understanding a heterogeneous syndromeCrit Care24102202010.1186/s13054-020-2778-x32204722 14FamousKRDelucchiKWareLBKangelarisKNLiuKDThompsonBTAcute respiratory distress" exact="syndrome" post="subphenotypes respond differently to randomized fluid management strategyAm J"/>
  <result pre="Crit Care Med195331338201710.1164/rccm.201603-0645OC27513822 15CalfeeCSDelucchiKLSinhaPMatthayMAHackettJShankar-HariMMcDowellCLaffeyJGOâ€²KaneCMMcAuleyDFet al.collab: Irish Critical Care Trials GroupAcute" exact="respiratory" post="distress syndrome subphenotypes and differential response to simvastatin: Secondary"/>
  <result pre="Med195331338201710.1164/rccm.201603-0645OC27513822 15CalfeeCSDelucchiKLSinhaPMatthayMAHackettJShankar-HariMMcDowellCLaffeyJGOâ€²KaneCMMcAuleyDFet al.collab: Irish Critical Care Trials GroupAcute respiratory distress" exact="syndrome" post="subphenotypes and differential response to simvastatin: Secondary analysis of"/>
  <result pre="GroupAcute respiratory distress syndrome subphenotypes and differential response to simvastatin:" exact="Secondary" post="analysis of a randomised controlled trialLancet Respir Med6691698201810.1016/S2213-2600(18)30177-230078618 16SinhaPDelucchiKLThompsonBTMcAuleyDFMatthayMALatent"/>
  <result pre="trialLancet Respir Med6691698201810.1016/S2213-2600(18)30177-230078618 16SinhaPDelucchiKLThompsonBTMcAuleyDFMatthayMALatent class analysis of ARDS subphenotypes: A" exact="secondary" post="analysis of the statins for acutely injured lungs from"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother5848754884201410.1128/AAC.03011-1424841269 18CascellaMRajnikMCuomoADulebohnSCDi"/>
  <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother5848754884201410.1128/AAC.03011-1424841269 18CascellaMRajnikMCuomoADulebohnSCDi NapoliRFeatures,"/>
  <result pre="medicine in oncology (Review)World Acad Sci J11131242019 20LevittJERogersAJProteomic study of" exact="acute" post="respiratory distress syndrome: Current knowledge and implications for drug"/>
  <result pre="in oncology (Review)World Acad Sci J11131242019 20LevittJERogersAJProteomic study of acute" exact="respiratory" post="distress syndrome: Current knowledge and implications for drug developmentExpert"/>
  <result pre="MERS coronaviruses with the antiviral interferon responseAdv Virus Res96219243201610.1016/bs.aivir.2016.08.00627712625 25ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKPerlmanSDysregulated" exact="type I" post="interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in"/>
  <result pre="25ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKPerlmanSDysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal" exact="pneumonia" post="in SARS-CoV-infected miceCell Host Microbe19181193201610.1016/j.chom.2016.01.00726867177 26BaughmanRPGuntherKLRashkinMCKeetonDAPattishallENChanges in the inflammatory"/>
  <result pre="Microbe19181193201610.1016/j.chom.2016.01.00726867177 26BaughmanRPGuntherKLRashkinMCKeetonDAPattishallENChanges in the inflammatory response of the lung during" exact="acute" post="respiratory distress syndrome: Prognostic indicatorsAm J Respir Crit Care"/>
  <result pre="26BaughmanRPGuntherKLRashkinMCKeetonDAPattishallENChanges in the inflammatory response of the lung during acute" exact="respiratory" post="distress syndrome: Prognostic indicatorsAm J Respir Crit Care Med1547681199610.1164/ajrccm.154.1.86807038680703"/>
  <result pre="Res46157161202010.1080/01902148.2020.175326632286085 28ColemanMDRhodesLEScottAKVerbovJLFriedmannPSBreckenridgeAMParkBKThe use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in" exact="dermatitis" post="herpetiformis patientsBr J Clin Pharmacol34244249199210.1111/j.1365-2125.1992.tb04131.x1389948 29MeoSAAlhowikanAMAl-KhlaiwiTMeoIMHalepotoDMIqbalMUsmaniAMHajjarWAhmedNNovel coronavirus 2019-nCoV: Prevalence,"/>
  <result pre="28ColemanMDRhodesLEScottAKVerbovJLFriedmannPSBreckenridgeAMParkBKThe use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis" exact="herpetiformis" post="patientsBr J Clin Pharmacol34244249199210.1111/j.1365-2125.1992.tb04131.x1389948 29MeoSAAlhowikanAMAl-KhlaiwiTMeoIMHalepotoDMIqbalMUsmaniAMHajjarWAhmedNNovel coronavirus 2019-nCoV: Prevalence, biological"/>
  <result pre="reevaluate the correlation between long-term effects of anthropogenic pollutants on" exact="viral" post="epidemic/pandemic events and prevalenceFood Chem Toxicol141111418202010.1016/j.fct.2020.11141832437891 32LuRZhaoXLiJNiuPYangBWuHWangWSongHHuangBZhuNet al.Genomic characterisation"/>
  <result pre="same cladeAntiviral Res176104742202010.1016/j.antiviral.2020.10474232057769 44KawaseMShiratoKvan der HoekLTaguchiFMatsuyamaSSimultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
  <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entryJ Virol8665376545201210.1128/JVI.00094-1222496216 45HoffmannMKleine-WeberHSchroederSKrÃ¼gerNHerrlerTErichsenSSchiergensTSHerrlerGWuNHNitscheAet al.SARS-CoV-2 cell entry"/>
  <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entryJ Virol8665376545201210.1128/JVI.00094-1222496216 45HoffmannMKleine-WeberHSchroederSKrÃ¼gerNHerrlerTErichsenSSchiergensTSHerrlerGWuNHNitscheAet al.SARS-CoV-2 cell entry depends"/>
  <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entryJ Virol8665376545201210.1128/JVI.00094-1222496216 45HoffmannMKleine-WeberHSchroederSKrÃ¼gerNHerrlerTErichsenSSchiergensTSHerrlerGWuNHNitscheAet al.SARS-CoV-2 cell entry depends on"/>
  <result pre="clinically proven protease inhibitorCell181271280.e8202010.1016/j.cell.2020.02.05232142651 46XiaSLiuMWangCXuWLanQFengSQiFBaoLDuLLiuSet al.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
  <result pre="cellsVirology51738201810.1016/j.virol.2017.12.01529275820 48ToturaALBavariSBroad-spectrum coronavirus antiviral drug discoveryExpert Opin Drug Discov14397412201910.1080/17460441.2019.158117130849247 49AmatngalimGDHiemstraPSAirway" exact="epithelial" post="cell function and respiratory host defense in chronic obstructive"/>
  <result pre="drug discoveryExpert Opin Drug Discov14397412201910.1080/17460441.2019.158117130849247 49AmatngalimGDHiemstraPSAirway epithelial cell function and" exact="respiratory" post="host defense in chronic obstructive pulmonary diseaseChin Med J"/>
  <result pre="Discov14397412201910.1080/17460441.2019.158117130849247 49AmatngalimGDHiemstraPSAirway epithelial cell function and respiratory host defense in" exact="chronic" post="obstructive pulmonary diseaseChin Med J (Engl)13110991107201810.4103/0366-6999.23074329692382 50ChiangJJDavisMEGackMURegulation of RIG-I-like"/>
  <result pre="epithelial cell function and respiratory host defense in chronic obstructive" exact="pulmonary" post="diseaseChin Med J (Engl)13110991107201810.4103/0366-6999.23074329692382 50ChiangJJDavisMEGackMURegulation of RIG-I-like receptor signaling"/>
  <result pre="J (Engl)13110991107201810.4103/0366-6999.23074329692382 50ChiangJJDavisMEGackMURegulation of RIG-I-like receptor signaling by host and" exact="viral" post="proteinsCytokine Growth Factor Rev25491505201410.1016/j.cytogfr.2014.06.00525023063 51SchneiderWMChevillotteMDRiceCMInterferonstimulated genes: A complex web"/>
  <result pre="J Immunol47615628201710.1002/eji.20164648428295214 58VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGSeidahNGNicholSTChloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J269200510.1186/1743-422X-2-6916115318 59SamarthSMcGregorKEnergetics based modeling of hydroxychloroquine and"/>
  <result pre="of novel coronavirus (SARS-CoV-2) from FDA approved drugsChemrxivOrg18202010.26434/chemrxiv.11860011 61DyallJGrossRKindrachukJJohnsonRFOlingerGGJrHensleyLEFriemanMBJahrlingPBMiddle East" exact="respiratory" post="syndrome and severe acute respiratory syndrome: Current therapeutic options"/>
  <result pre="novel coronavirus (SARS-CoV-2) from FDA approved drugsChemrxivOrg18202010.26434/chemrxiv.11860011 61DyallJGrossRKindrachukJJohnsonRFOlingerGGJrHensleyLEFriemanMBJahrlingPBMiddle East respiratory" exact="syndrome" post="and severe acute respiratory syndrome: Current therapeutic options and"/>
  <result pre="from FDA approved drugsChemrxivOrg18202010.26434/chemrxiv.11860011 61DyallJGrossRKindrachukJJohnsonRFOlingerGGJrHensleyLEFriemanMBJahrlingPBMiddle East respiratory syndrome and severe" exact="acute" post="respiratory syndrome: Current therapeutic options and potential targets for"/>
  <result pre="FDA approved drugsChemrxivOrg18202010.26434/chemrxiv.11860011 61DyallJGrossRKindrachukJJohnsonRFOlingerGGJrHensleyLEFriemanMBJahrlingPBMiddle East respiratory syndrome and severe acute" exact="respiratory" post="syndrome: Current therapeutic options and potential targets for novel"/>
  <result pre="studyChemRxiv2020Preprint. 10.26434/chemrxiv.12038604.v1 66ColemanCMSiskJMMingoRMNelsonEAWhiteJMFriemanMBAbelson kinase inhibitors are potent inhibitors of severe" exact="acute" post="respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus"/>
  <result pre="10.26434/chemrxiv.12038604.v1 66ColemanCMSiskJMMingoRMNelsonEAWhiteJMFriemanMBAbelson kinase inhibitors are potent inhibitors of severe acute" exact="respiratory" post="syndrome coronavirus and Middle East respiratory syndrome coronavirus fusionJ"/>
  <result pre="66ColemanCMSiskJMMingoRMNelsonEAWhiteJMFriemanMBAbelson kinase inhibitors are potent inhibitors of severe acute respiratory" exact="syndrome" post="coronavirus and Middle East respiratory syndrome coronavirus fusionJ Virol9089248933201610.1128/JVI.01429-1627466418"/>
  <result pre="inhibitors of severe acute respiratory syndrome coronavirus and Middle East" exact="respiratory" post="syndrome coronavirus fusionJ Virol9089248933201610.1128/JVI.01429-1627466418 67SiskJMFriemanMBMachamerCECoronavirus S protein-induced fusion is"/>
  <result pre="of severe acute respiratory syndrome coronavirus and Middle East respiratory" exact="syndrome" post="coronavirus fusionJ Virol9089248933201610.1128/JVI.01429-1627466418 67SiskJMFriemanMBMachamerCECoronavirus S protein-induced fusion is blocked"/>
  <result pre="and RNA-dependent RNA polymerase (RdRp)ChemRxiv Preprint10.26434/chemrxiv.12051927.v2 70MohammadiNInhibitory effect of eight" exact="secondary" post="metabolites from conventional medicinal plants on COVID-19 virus protease"/>
  <result pre="protease by molecular docking analysisChemRxiv2020Preprint. 10.26434/chemrxiv.11987475.v1 71BoschBJMartinaBEEVan Der ZeeRLepaultJHaijemaBJVersluisCHeckAJDe GrootROsterhausADRottierPJSevere" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein"/>
  <result pre="by molecular docking analysisChemRxiv2020Preprint. 10.26434/chemrxiv.11987475.v1 71BoschBJMartinaBEEVan Der ZeeRLepaultJHaijemaBJVersluisCHeckAJDe GrootROsterhausADRottierPJSevere acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad"/>
  <result pre="molecular docking analysisChemRxiv2020Preprint. 10.26434/chemrxiv.11987475.v1 71BoschBJMartinaBEEVan Der ZeeRLepaultJHaijemaBJVersluisCHeckAJDe GrootROsterhausADRottierPJSevere acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived"/>
  <result pre="10.26434/chemrxiv.11987475.v1 71BoschBJMartinaBEEVan Der ZeeRLepaultJHaijemaBJVersluisCHeckAJDe GrootROsterhausADRottierPJSevere acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="inhibition using spike protein heptad repeat-derived peptidesProc Natl Acad"/>
  <result pre="repeat-derived peptidesProc Natl Acad Sci USA10184558460200410.1073/pnas.040057610115150417 72YangZ-YHuangYGaneshLLeungKKongWPSchwartzOSubbaraoKNabelGJpH-dependent entry of severe" exact="acute" post="respiratory syndrome coronavirus is mediated by the spike glycoprotein"/>
  <result pre="peptidesProc Natl Acad Sci USA10184558460200410.1073/pnas.040057610115150417 72YangZ-YHuangYGaneshLLeungKKongWPSchwartzOSubbaraoKNabelGJpH-dependent entry of severe acute" exact="respiratory" post="syndrome coronavirus is mediated by the spike glycoprotein and"/>
  <result pre="Natl Acad Sci USA10184558460200410.1073/pnas.040057610115150417 72YangZ-YHuangYGaneshLLeungKKongWPSchwartzOSubbaraoKNabelGJpH-dependent entry of severe acute respiratory" exact="syndrome" post="coronavirus is mediated by the spike glycoprotein and enhanced"/>
  <result pre="Virol7856425650200410.1128/JVI.78.11.5642-5650.200415140961 73ZhaoJWohlford-LenaneCZhaoJFlemingELaneTEMcCrayPBJrPerlmanSIntranasal treatment with poly(Iâ€¢C) protects aged mice from lethal" exact="respiratory" post="virus infectionsJ Virol861141611424201210.1128/JVI.01410-1222915814 74MianMFAhmedANRadMBabaianABowdishDAshkarAALength of dsRNA (poly I:C) drives"/>
  <result pre="Chem2753674136749200010.1074/jbc.M00384820010958789 76ChannappanavarRLuLXiaSDuLMeyerholzDKPerlmanSJiangSProtective effect of intranasal regimens containing peptidic Middle East" exact="respiratory" post="syndrome coronavirus fusion inhibitor against MERS-CoV infection. - Abstract"/>
  <result pre="76ChannappanavarRLuLXiaSDuLMeyerholzDKPerlmanSJiangSProtective effect of intranasal regimens containing peptidic Middle East respiratory" exact="syndrome" post="coronavirus fusion inhibitor against MERS-CoV infection. - Abstract -"/>
  <result pre="systemScience327291295201010.1126/science.118302120075244 79SainzBJrMosselECPetersCJGarryRFInterferon-beta and interferon-gamma synergistically inhibit the replication of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV)Virology3291117200410.1016/j.virol.2004.08.01115476870 80DerSDZhouAWilliamsBRGSilvermanRHIdentification of genes differentially regulated"/>
  <result pre="79SainzBJrMosselECPetersCJGarryRFInterferon-beta and interferon-gamma synergistically inhibit the replication of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV)Virology3291117200410.1016/j.virol.2004.08.01115476870 80DerSDZhouAWilliamsBRGSilvermanRHIdentification of genes differentially regulated by"/>
  <result pre="RNA screen identifies proviral and antiviral host factors in severe" exact="acute" post="respiratory syndrome coronavirus replication, including double-stranded RNA-activated protein kinase"/>
  <result pre="screen identifies proviral and antiviral host factors in severe acute" exact="respiratory" post="syndrome coronavirus replication, including double-stranded RNA-activated protein kinase and"/>
  <result pre="identifies proviral and antiviral host factors in severe acute respiratory" exact="syndrome" post="coronavirus replication, including double-stranded RNA-activated protein kinase and early"/>
  <result pre="early secretory pathway proteinsJ Virol8983188333201510.1128/JVI.01029-1526041291 85NewtonDARaoKMKDluhyRABaatzJEHemoglobin is expressed by alveolar" exact="epithelial" post="cellsJ Biol Chem28156685676200610.1074/jbc.M50931420016407281 86AldajaniWASalazarFSewellHFKnoxAGhaemmaghamiAMExpression and regulation of immunemodulatory enzyme"/>
  <result pre="regulation of immunemodulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway" exact="epithelial" post="cells and its effect on T cell activationOncotarget75760657617201610.18632/oncotarget.1158627613847 87MondanelliGBianchiRPallottaMTOrabonaCAlbiniEIaconoABelladonnaMLVaccaCFallarinoFMacchiaruloAet"/>
  <result pre="accessory protein vpu downregulates peroxisome biogenesisMBio1111202010.1128/mBio.03395-19 91ZhengCSuCHerpes simplex virus 1" exact="infection" post="dampens the immediate early antiviral innate immunity signaling from"/>
  <result pre="Antiviral response and beyondInt J Mol Sci2020201910.3390/ijms20153795 93SkalnyAVRinkLAjsuvakovaOPAschnerMGritsenkoVAAlekseenkoSISvistunovAAPetrakisDSpandidosDAAasethJet al.Zinc and" exact="respiratory" post="tract infections: Perspectives for COVID-19 (Review)Int J Mol Med4617262020"/>
  <result pre="COVID-19 (Review)Int J Mol Med4617262020 94GastaminzaPWhitten-BauerCChisariFVUnbiased probing of the entire" exact="hepatitis C" post="virus life cycle identifies clinical compounds that target multiple"/>
  <result pre="Natl Acad Sci USA107291296201010.1073/pnas.091296610719995961 95SimmonsGGosaliaDNRennekampAJReevesJDDiamondSLBatesPInhibitors of cathepsin L prevent severe" exact="acute" post="respiratory syndrome coronavirus entryProc Natl Acad Sci USA1021187611881200510.1073/pnas.050557710216081529 96BlanchardEBelouzardSGoueslainLWakitaTDubuissonJWychowskiCRouillÃ©YHepatitis"/>
  <result pre="Acad Sci USA107291296201010.1073/pnas.091296610719995961 95SimmonsGGosaliaDNRennekampAJReevesJDDiamondSLBatesPInhibitors of cathepsin L prevent severe acute" exact="respiratory" post="syndrome coronavirus entryProc Natl Acad Sci USA1021187611881200510.1073/pnas.050557710216081529 96BlanchardEBelouzardSGoueslainLWakitaTDubuissonJWychowskiCRouillÃ©YHepatitis C"/>
  <result pre="Sci USA107291296201010.1073/pnas.091296610719995961 95SimmonsGGosaliaDNRennekampAJReevesJDDiamondSLBatesPInhibitors of cathepsin L prevent severe acute respiratory" exact="syndrome" post="coronavirus entryProc Natl Acad Sci USA1021187611881200510.1073/pnas.050557710216081529 96BlanchardEBelouzardSGoueslainLWakitaTDubuissonJWychowskiCRouillÃ©YHepatitis C virus"/>
  <result pre="neutrophil activationJ Immunol16248494857199910202029 98RotsteinODFiegelVDSimmonsRLKnightonDRThe deleterious effect of reduced pH and" exact="hypoxia" post="on neutrophil migration in vitroJ Surg Res45298303198810.1016/0022-4804(88)90079-03411954 99LardnerAThe effects"/>
  <result pre="Clin Invest7610791089198510.1172/JCI1120612995444 101SeverinTMÃ¼llerBGieseGUhlBWolfBHauschildtSKreutzWpH-dependent LAK cell cytotoxicityTumour Biol15304310199410.1159/0002179057991991 102KellumJASongMLiJScience review: extracellular" exact="acidosis" post="and the immune response: clinical and physiologic implicationsCrit Care8331336200410.1186/cc290015469594"/>
  <result pre="of anti-influenza action of arbidolAntiviral Res81132140200910.1016/j.antiviral.2008.10.00919028526 105BhargavaMBeckerTLVikenKJJagtapPDDeySSteinbachMSWuBKumarVBittermanPBIngbarDHet al.Proteomic profiles in" exact="acute" post="respiratory distress syndrome differentiates survivors from non-survivorsPLoS One9e109713201410.1371/journal.pone.010971325290099 106ShorttKChaudharySGrigoryevDHeruthDPVenkitachalamLZhangLQYeSQIdentification"/>
  <result pre="anti-influenza action of arbidolAntiviral Res81132140200910.1016/j.antiviral.2008.10.00919028526 105BhargavaMBeckerTLVikenKJJagtapPDDeySSteinbachMSWuBKumarVBittermanPBIngbarDHet al.Proteomic profiles in acute" exact="respiratory" post="distress syndrome differentiates survivors from non-survivorsPLoS One9e109713201410.1371/journal.pone.010971325290099 106ShorttKChaudharySGrigoryevDHeruthDPVenkitachalamLZhangLQYeSQIdentification of"/>
  <result pre="of arbidolAntiviral Res81132140200910.1016/j.antiviral.2008.10.00919028526 105BhargavaMBeckerTLVikenKJJagtapPDDeySSteinbachMSWuBKumarVBittermanPBIngbarDHet al.Proteomic profiles in acute respiratory distress" exact="syndrome" post="differentiates survivors from non-survivorsPLoS One9e109713201410.1371/journal.pone.010971325290099 106ShorttKChaudharySGrigoryevDHeruthDPVenkitachalamLZhangLQYeSQIdentification of novel single"/>
  <result pre="non-survivorsPLoS One9e109713201410.1371/journal.pone.010971325290099 106ShorttKChaudharySGrigoryevDHeruthDPVenkitachalamLZhangLQYeSQIdentification of novel single nucleotide polymorphisms associated with" exact="acute" post="respiratory distress syndrome by exome-seqPLoS One9e111953201410.1371/journal.pone.011195325372662 107TejeraPMeyerNJChenFFengRZhaoYOâ€²MahonyDSLiLSheuCCZhaiRWangZet al.Distinct and"/>
  <result pre="One9e109713201410.1371/journal.pone.010971325290099 106ShorttKChaudharySGrigoryevDHeruthDPVenkitachalamLZhangLQYeSQIdentification of novel single nucleotide polymorphisms associated with acute" exact="respiratory" post="distress syndrome by exome-seqPLoS One9e111953201410.1371/journal.pone.011195325372662 107TejeraPMeyerNJChenFFengRZhaoYOâ€²MahonyDSLiLSheuCCZhaiRWangZet al.Distinct and replicable"/>
  <result pre="of novel single nucleotide polymorphisms associated with acute respiratory distress" exact="syndrome" post="by exome-seqPLoS One9e111953201410.1371/journal.pone.011195325372662 107TejeraPMeyerNJChenFFengRZhaoYOâ€²MahonyDSLiLSheuCCZhaiRWangZet al.Distinct and replicable genetic risk"/>
  <result pre="exome-seqPLoS One9e111953201410.1371/journal.pone.011195325372662 107TejeraPMeyerNJChenFFengRZhaoYOâ€²MahonyDSLiLSheuCCZhaiRWangZet al.Distinct and replicable genetic risk factors for" exact="acute" post="respiratory distress syndrome of pulmonary or extrapulmonary originJ Med"/>
  <result pre="One9e111953201410.1371/journal.pone.011195325372662 107TejeraPMeyerNJChenFFengRZhaoYOâ€²MahonyDSLiLSheuCCZhaiRWangZet al.Distinct and replicable genetic risk factors for acute" exact="respiratory" post="distress syndrome of pulmonary or extrapulmonary originJ Med Genet49671680201210.1136/jmedgenet-2012-10097223048207"/>
  <result pre="al.Distinct and replicable genetic risk factors for acute respiratory distress" exact="syndrome" post="of pulmonary or extrapulmonary originJ Med Genet49671680201210.1136/jmedgenet-2012-10097223048207 108LynnHSunXCasanovaNGonzales-GarayMBimeCGarciaJGNGenomic and"/>
  <result pre="replicable genetic risk factors for acute respiratory distress syndrome of" exact="pulmonary" post="or extrapulmonary originJ Med Genet49671680201210.1136/jmedgenet-2012-10097223048207 108LynnHSunXCasanovaNGonzales-GarayMBimeCGarciaJGNGenomic and genetic approaches"/>
  <result pre="extrapulmonary originJ Med Genet49671680201210.1136/jmedgenet-2012-10097223048207 108LynnHSunXCasanovaNGonzales-GarayMBimeCGarciaJGNGenomic and genetic approaches to deciphering" exact="acute" post="respiratory distress syndrome risk and mortalityAntioxid Redox Signal3110271052201910.1089/ars.2018.770131016989 109MarshallRPWebbSBellinganGJMontgomeryHEChaudhariBMcAnultyRJHumphriesSEHillMRLaurentGJAngiotensin"/>
  <result pre="originJ Med Genet49671680201210.1136/jmedgenet-2012-10097223048207 108LynnHSunXCasanovaNGonzales-GarayMBimeCGarciaJGNGenomic and genetic approaches to deciphering acute" exact="respiratory" post="distress syndrome risk and mortalityAntioxid Redox Signal3110271052201910.1089/ars.2018.770131016989 109MarshallRPWebbSBellinganGJMontgomeryHEChaudhariBMcAnultyRJHumphriesSEHillMRLaurentGJAngiotensin converting"/>
  <result pre="Genet49671680201210.1136/jmedgenet-2012-10097223048207 108LynnHSunXCasanovaNGonzales-GarayMBimeCGarciaJGNGenomic and genetic approaches to deciphering acute respiratory distress" exact="syndrome" post="risk and mortalityAntioxid Redox Signal3110271052201910.1089/ars.2018.770131016989 109MarshallRPWebbSBellinganGJMontgomeryHEChaudhariBMcAnultyRJHumphriesSEHillMRLaurentGJAngiotensin converting enzyme insertion/deletion"/>
  <result pre="enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in" exact="acute" post="respiratory distress syndromeAm J Respir Crit Care Med166646650200210.1164/rccm.210808612204859 110ItoyamaSKeichoNQuyTPhiNCLongHTHaLDBanVVOhashiJHijikataMMatsushitaIet"/>
  <result pre="insertion/deletion polymorphism is associated with susceptibility and outcome in acute" exact="respiratory" post="distress syndromeAm J Respir Crit Care Med166646650200210.1164/rccm.210808612204859 110ItoyamaSKeichoNQuyTPhiNCLongHTHaLDBanVVOhashiJHijikataMMatsushitaIet al.ACE1"/>
  <result pre="of association between angiotensin converting enzyme polymorphism and development of" exact="adult" post="respiratory distress syndrome in patients with severe acute respiratory"/>
  <result pre="association between angiotensin converting enzyme polymorphism and development of adult" exact="respiratory" post="distress syndrome in patients with severe acute respiratory syndrome:"/>
  <result pre="angiotensin converting enzyme polymorphism and development of adult respiratory distress" exact="syndrome" post="in patients with severe acute respiratory syndrome: A case"/>
  <result pre="development of adult respiratory distress syndrome in patients with severe" exact="acute" post="respiratory syndrome: A case control studyBMC Infect Dis526200510.1186/1471-2334-5-2615819995 112FourrierFChopinCWallaertBWattrePMangalaboyiJDurocherADuboisDWattelFAngiotensin-converting"/>
  <result pre="of adult respiratory distress syndrome in patients with severe acute" exact="respiratory" post="syndrome: A case control studyBMC Infect Dis526200510.1186/1471-2334-5-2615819995 112FourrierFChopinCWallaertBWattrePMangalaboyiJDurocherADuboisDWattelFAngiotensin-converting enzyme"/>
  <result pre="A case control studyBMC Infect Dis526200510.1186/1471-2334-5-2615819995 112FourrierFChopinCWallaertBWattrePMangalaboyiJDurocherADuboisDWattelFAngiotensin-converting enzyme in human" exact="adult" post="respiratory distress syndromeChest83593597198310.1378/chest.83.4.5936299654 113ImaiYKubaKRaoSHuanYGuoFGuanBYangPSaraoRWadaTLeong-PoiHet al.Angiotensin-converting enzyme 2 protects from"/>
  <result pre="case control studyBMC Infect Dis526200510.1186/1471-2334-5-2615819995 112FourrierFChopinCWallaertBWattrePMangalaboyiJDurocherADuboisDWattelFAngiotensin-converting enzyme in human adult" exact="respiratory" post="distress syndromeChest83593597198310.1378/chest.83.4.5936299654 113ImaiYKubaKRaoSHuanYGuoFGuanBYangPSaraoRWadaTLeong-PoiHet al.Angiotensin-converting enzyme 2 protects from severe"/>
  <result pre="respiratory distress syndromeChest83593597198310.1378/chest.83.4.5936299654 113ImaiYKubaKRaoSHuanYGuoFGuanBYangPSaraoRWadaTLeong-PoiHet al.Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature436112116200510.1038/nature0371216001071 114ArndtPGYoungSKPochKRNickJAFalkSSchrierRWWorthenGSSystemic inhibition of the angiotensin-converting enzyme limits"/>
  <result pre="pathwaysJ Immunol17772337241200610.4049/jimmunol.177.10.723317082641 115KimJChoiSMLeeJParkYSLeeCHYimJJYooCGKimYWHanSKLeeSMEffect of renin-angiotensin system blockage in patients with" exact="acute" post="respiratory distress syndrome: A retrospective case control studyKorean J"/>
  <result pre="Immunol17772337241200610.4049/jimmunol.177.10.723317082641 115KimJChoiSMLeeJParkYSLeeCHYimJJYooCGKimYWHanSKLeeSMEffect of renin-angiotensin system blockage in patients with acute" exact="respiratory" post="distress syndrome: A retrospective case control studyKorean J Crit"/>
  <result pre="commander in innate immune responsesSci Signal3pe27201010.1126/scisignal.3135pe2720716762 123KeyaertsEVijgenLChenLMaesPHedenstiernaGVan RanstMInhibition of SARS-coronavirus" exact="infection" post="in vitro by S-nitroso-N- acetylpenicillamine, a nitric oxide donor"/>
  <result pre="by S-nitroso-N- acetylpenicillamine, a nitric oxide donor compoundInternational Journal of" exact="Infectious" post="Diseases Int J Infect Dis8223226200410.1016/j.ijid.2004.04.012 124AkerstrÃ¶mSMousavi-JaziMKlingstrÃ¶mJLeijonMLundkvistAMirazimiANitric oxide inhibits the"/>
  <result pre="S-nitroso-N- acetylpenicillamine, a nitric oxide donor compoundInternational Journal of Infectious" exact="Diseases" post="Int J Infect Dis8223226200410.1016/j.ijid.2004.04.012 124AkerstrÃ¶mSMousavi-JaziMKlingstrÃ¶mJLeijonMLundkvistAMirazimiANitric oxide inhibits the replication"/>
  <result pre="Infect Dis8223226200410.1016/j.ijid.2004.04.012 124AkerstrÃ¶mSMousavi-JaziMKlingstrÃ¶mJLeijonMLundkvistAMirazimiANitric oxide inhibits the replication cycle of severe" exact="acute" post="respiratory syndrome coronavirusJ Virol7919661969200510.1128/JVI.79.3.1966-1969.200515650225 125CinatlJMorgensternBBauerGChandraPRabenauHDoerrHWTreatment of SARS with human"/>
  <result pre="Dis8223226200410.1016/j.ijid.2004.04.012 124AkerstrÃ¶mSMousavi-JaziMKlingstrÃ¶mJLeijonMLundkvistAMirazimiANitric oxide inhibits the replication cycle of severe acute" exact="respiratory" post="syndrome coronavirusJ Virol7919661969200510.1128/JVI.79.3.1966-1969.200515650225 125CinatlJMorgensternBBauerGChandraPRabenauHDoerrHWTreatment of SARS with human interferonsLancet362293294200310.1016/S0140-6736(03)13973-612892961"/>
  <result pre="124AkerstrÃ¶mSMousavi-JaziMKlingstrÃ¶mJLeijonMLundkvistAMirazimiANitric oxide inhibits the replication cycle of severe acute respiratory" exact="syndrome" post="coronavirusJ Virol7919661969200510.1128/JVI.79.3.1966-1969.200515650225 125CinatlJMorgensternBBauerGChandraPRabenauHDoerrHWTreatment of SARS with human interferonsLancet362293294200310.1016/S0140-6736(03)13973-612892961 126KarupiahGXieQWBullerRMLNathanCDuarteCMacMickingJDInhibition"/>
  <result pre="coronavirusJ Virol7919661969200510.1128/JVI.79.3.1966-1969.200515650225 125CinatlJMorgensternBBauerGChandraPRabenauHDoerrHWTreatment of SARS with human interferonsLancet362293294200310.1016/S0140-6736(03)13973-612892961 126KarupiahGXieQWBullerRMLNathanCDuarteCMacMickingJDInhibition of" exact="viral" post="replication by interferon-Î³-induced nitric oxide synthaseScience26114451448199310.1126/science.76901567690156 127BurrackKSMorrisonTEThe role of"/>
  <result pre="between catalase inhibitors and modulators of nitric oxide metabolism on" exact="tumor" post="cell apoptosisAnticancer Res3453375350201425275027 135ThomasSRMohrDStockerRNitric oxide inhibits indoleamine 2,3-dioxygenase activity"/>
  <result pre="lymphocyte subpopulationsJPEN J Parenter Enteral Nutr252329200110.1177/01486071010250012311190986 139de JongeWJKwikkersKLte VeldeAAvan DeventerSJNolteMAMebiusRERuijterJMLamersMCLamersWHArginine" exact="deficiency" post="affects early B cell maturation and lymphoid organ development"/>
  <result pre="cell therapyCytotherapy17613620201510.1016/j.jcyt.2015.01.00425747742 143AndersonRAssessment of oral ascorbate in three children with" exact="chronic" post="granulomatous disease and defective neutrophil motility over a 2-year"/>
  <result pre="143AndersonRAssessment of oral ascorbate in three children with chronic granulomatous" exact="disease" post="and defective neutrophil motility over a 2-year periodClin Exp"/>
  <result pre="of ascorbic acid on neutrophil function. Studies on normal and" exact="chronic" post="granulomatous disease neutrophilsActa Vitaminol Enzymol416316819827124564 145MoraesMPde Los SantosTKosterMTurecekTWangHAndreyevVGGrubmanMJEnhanced antiviral"/>
  <result pre="acid on neutrophil function. Studies on normal and chronic granulomatous" exact="disease" post="neutrophilsActa Vitaminol Enzymol416316819827124564 145MoraesMPde Los SantosTKosterMTurecekTWangHAndreyevVGGrubmanMJEnhanced antiviral activity against"/>
  <result pre="neutrophilsActa Vitaminol Enzymol416316819827124564 145MoraesMPde Los SantosTKosterMTurecekTWangHAndreyevVGGrubmanMJEnhanced antiviral activity against foot-and-mouth" exact="disease" post="virus by a combination of type I and II"/>
  <result pre="antiviral activity against foot-and-mouth disease virus by a combination of" exact="type I" post="and II porcine interferonsJ Virol8171247135200710.1128/JVI.02775-0617459931 146PengTZhuJHwangboYCoreyLBumgarnerREIndependent and cooperative antiviral"/>
  <result pre="cooperative antiviral actions of beta interferon and gamma interferon against" exact="herpes" post="simplex virus replication in primary human fibroblastsJ Virol8219341945200810.1128/JVI.01649-0718057251 147BarteeEMohamedMRLopezMCBakerHVMcFaddenGThe"/>
  <result pre="interferon and gamma interferon against herpes simplex virus replication in" exact="primary" post="human fibroblastsJ Virol8219341945200810.1128/JVI.01649-0718057251 147BarteeEMohamedMRLopezMCBakerHVMcFaddenGThe addition of tumor necrosis factor"/>
  <result pre="virus replication in primary human fibroblastsJ Virol8219341945200810.1128/JVI.01649-0718057251 147BarteeEMohamedMRLopezMCBakerHVMcFaddenGThe addition of" exact="tumor" post="necrosis factor plus beta interferon induces a novel synergistic"/>
  <result pre="interferon induces a novel synergistic antiviral state against poxviruses in" exact="primary" post="human fibroblastsJ Virol83498511200910.1128/JVI.01376-0818971273 148PageCGoicocheaLMatthewsKZhangYKloverPHoltzmanMJHennighausenLFriemanMInduction of alternatively activated macrophages enhances"/>
  <result pre="Virol83498511200910.1128/JVI.01376-0818971273 148PageCGoicocheaLMatthewsKZhangYKloverPHoltzmanMJHennighausenLFriemanMInduction of alternatively activated macrophages enhances pathogenesis during severe" exact="acute" post="respiratory syndrome coronavirus infectionJ Virol861333413349201210.1128/JVI.01689-1223015710 149BlockGJensenCDDalviTBNorkusEPHudesMCrawfordPBHollandNFungEBSchumacherLHarmatzPVitamin C treatment reduces"/>
  <result pre="148PageCGoicocheaLMatthewsKZhangYKloverPHoltzmanMJHennighausenLFriemanMInduction of alternatively activated macrophages enhances pathogenesis during severe acute" exact="respiratory" post="syndrome coronavirus infectionJ Virol861333413349201210.1128/JVI.01689-1223015710 149BlockGJensenCDDalviTBNorkusEPHudesMCrawfordPBHollandNFungEBSchumacherLHarmatzPVitamin C treatment reduces elevated"/>
  <result pre="of alternatively activated macrophages enhances pathogenesis during severe acute respiratory" exact="syndrome" post="coronavirus infectionJ Virol861333413349201210.1128/JVI.01689-1223015710 149BlockGJensenCDDalviTBNorkusEPHudesMCrawfordPBHollandNFungEBSchumacherLHarmatzPVitamin C treatment reduces elevated C-reactive"/>
  <result pre="elevated C-reactive proteinFree Radic Biol Med467077200910.1016/j.freeradbiomed.2008.09.03018952164 150KimWYJungJWChoiJCShinJWKimJYSubphenotypes in patients with" exact="septic shock" post="receiving vitamin C, hydrocortisone, and thiamine: A retrospective cohort"/>
  <result pre="care unit patientsCrit Care Med28643648200010.1097/00003246-200003000-0000710752808 160LuikingYCPoezeMDeutzNEArginine infusion in patients with" exact="septic shock" post="increases nitric oxide production without haemodynamic instabilityClin Sci (Lond)1285767201510.1042/CS2014034325036556"/>
  <result pre="infusion during resuscitation for hemorrhagic shock: Impact and mechanismJ Trauma" exact="Acute" post="Care Surg72397402201210.1097/TA.0b013e3181d039fd22439203 165WuFWilsonJXTymlKAscorbate protects against impaired arteriolar constriction in"/>
  <result pre="C infusion on organ failure and biomarkers of inflammation and" exact="vascular" post="injury in patients with sepsis and severe acute respiratory"/>
  <result pre="inflammation and vascular injury in patients with sepsis and severe" exact="acute" post="respiratory failure: The CITRIS-ALI Randomized Clinical TrialJAMA32212611270201910.1001/jama.2019.1182531573637 168CalinaDDoceaAOPetrakisDEgorovAMIshmukhametovAAGabibovAGShtilmanMIKostoffRCarvalhoFVincetiMet al.Towards"/>
  <result pre="and vascular injury in patients with sepsis and severe acute" exact="respiratory" post="failure: The CITRIS-ALI Randomized Clinical TrialJAMA32212611270201910.1001/jama.2019.1182531573637 168CalinaDDoceaAOPetrakisDEgorovAMIshmukhametovAAGabibovAGShtilmanMIKostoffRCarvalhoFVincetiMet al.Towards effective"/>
  <result pre="isoenzyme and blood lymphocyte subsets as prognostic indicators for severe" exact="acute" post="respiratory syndromeJ Intern Med255512518200410.1111/j.1365-2796.2004.01323.x15049886 170HicksCWWangDDayaNRWindhamBGBallantyneCMMatsushitaKSelvinEAssociations of cardiac, kidney, and"/>
  <result pre="and blood lymphocyte subsets as prognostic indicators for severe acute" exact="respiratory" post="syndromeJ Intern Med255512518200410.1111/j.1365-2796.2004.01323.x15049886 170HicksCWWangDDayaNRWindhamBGBallantyneCMMatsushitaKSelvinEAssociations of cardiac, kidney, and diabetes"/>
  <result pre="acute respiratory syndromeJ Intern Med255512518200410.1111/j.1365-2796.2004.01323.x15049886 170HicksCWWangDDayaNRWindhamBGBallantyneCMMatsushitaKSelvinEAssociations of cardiac, kidney, and" exact="diabetes" post="biomarkers with peripheral neuropathy among older adults in the"/>
  <result pre="Intern Med255512518200410.1111/j.1365-2796.2004.01323.x15049886 170HicksCWWangDDayaNRWindhamBGBallantyneCMMatsushitaKSelvinEAssociations of cardiac, kidney, and diabetes biomarkers with" exact="peripheral neuropathy" post="among older adults in the atherosclerosis risk in communities"/>
  <result pre="Med255512518200410.1111/j.1365-2796.2004.01323.x15049886 170HicksCWWangDDayaNRWindhamBGBallantyneCMMatsushitaKSelvinEAssociations of cardiac, kidney, and diabetes biomarkers with peripheral" exact="neuropathy" post="among older adults in the atherosclerosis risk in communities"/>
  <result pre="diabetes biomarkers with peripheral neuropathy among older adults in the" exact="atherosclerosis" post="risk in communities (ARIC) studyClin Chem66686696202010.1093/clinchem/hvaa05132268368 Figure 1 SARS-CoV2"/>
  <result pre="proteins and some of their known pro-viral actions. Figure 2" exact="Severe" post="COVID-19, interstitial hemorrhage, porphyria, necrosis. (A) Bullous porphyria and"/>
  <result pre="Figure 2 Severe COVID-19, interstitial hemorrhage, porphyria, necrosis. (A) Bullous" exact="porphyria" post="and necrosis in literature (39). (B) Our own experience."/>
  <result pre="administration has benefit on 90-day survival (HARP-2) No No ARDS," exact="acute" post="respiratory distress. Table II FDA-approved drugs with SARS-CoV2 antiviral"/>
  <result pre="has benefit on 90-day survival (HARP-2) No No ARDS, acute" exact="respiratory" post="distress. Table II FDA-approved drugs with SARS-CoV2 antiviral actions."/>
  <result pre="II FDA-approved drugs with SARS-CoV2 antiviral actions. Substance analyzed (Ref.)" exact="Viral" post="molecule inhibited; mechanism Method and/or software used for testing"/>
  <result pre="testing FDA approved drugs Hydroxychloroquine and azithromycin (59) Spike (S)" exact="Protein" post="- binding motifs of ACE2 receptor; Virtualized quantum mechanical"/>
  <result pre="heme, ORF8, surface glycoproteins to porphyrins Simulated molecular docking of" exact="viral" post="proteins with human heme or porphyrins with (LibDock tool)"/>
  <result pre="porphyrin, prevent virus entering host cells Simulated molecular docking of" exact="viral" post="proteins with human heme or porphyrins with (LibDock tool)"/>
  <result pre="Table III Natural compounds with antiviral actions. Substance analyzed (Ref.)" exact="Viral" post="molecule inhibited; mechanism Method and/or software used for testing"/>
  <result pre="inhibitor Structure of metabolite and COVID_19 protease from PubChem and" exact="Protein" post="Data Bank (PDB); molecular docking by MVD (Molegro Virtual"/>
 </snippets>
</snippetsTree>
